Imaging β-amyloid using [18F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis

@article{Heurling2015ImagingU,
  title={Imaging $\beta$-amyloid using [18F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis},
  author={Kerstin Heurling and Antoine Leuzy and Eduardo R. Zimmer and Mark Lubberink and Agneta Nordberg},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2015},
  volume={43},
  pages={362-373}
}
In Alzheimer’s disease (AD), the deposition of β-amyloid (Aβ) is hypothesized to result in a series of secondary neurodegenerative processes, leading ultimately to synaptic dysfunction and neuronal loss. Since the advent of the first Aβ-specific positron emission tomography (PET) ligand, 11C-Pittsburgh compound B ([11C]PIB), several 18F ligands have been developed that circumvent the limitations of [11C]PIB tied to its short half-life. To date, three such compounds have been approved for… 
View on Springer
ncbi.nlm.nih.gov
29 Citations
Background Citations
3

29 Citations

Citation Type

Citation Type

[18F]Amylovis as a Potential PET Probe for β-Amyloid Plaque: Synthesis, In Silico, In vitro and In vivo Evaluations
TLDR
The in silico, in vitro and in vivo results justify that [18F]Amylovis should be studied as a promissory PET imaging agent to detect the presence of Aβ senile plaques.
Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies
PurposeTau deposition is a key pathological feature of Alzheimer’s disease (AD) and other neurodegenerative disorders. The spreading of tau neurofibrillary tangles across defined brain regions…
Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies
TLDR
A dual-time-window protocol of 0–30 and 90–110 min (=maximum of 60’min interval) allows for accurate estimation of BPND values for both tracers and demonstrates an increased bias in amyloid estimate for larger intervals and higher noise levels.
99mTc-labeled small molecules for diagnosis of Alzheimer's disease: Past, recent and future perspectives.
TLDR
The findings of this review confirm the importance of 99mTc-labeled small molecules for AD imaging and future studies based on the pharmacophore of these designed compounds are needed for improvement of these molecules for clinical application.
Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework
Validation of a spatial normalization method using a principal component derived adaptive template for [18F]florbetaben PET.
TLDR
This method allows for robust and accurate registration of [18F]florbetaben images to template space, without the need for an MR image, and may prove of value in clinical and research settings.
Synthesis and biological evaluation of curcumin analogs as β-amyloid imaging agents.
TLDR
The results strongly suggested that [125I]4e might be developed into potential amyloid imaging agent for the detection of senile plaques in AD.
68Ga-Labeled Benzothiazole Derivatives for Imaging Aβ Plaques in Cerebral Amyloid Angiopathy
TLDR
Novel 1,4,7-triazacyclononane-based bifunctional chelators that incorporate a benzothiazole moiety as the Aβ-binding fragment and form charged and neutral species with 68Ga3+.
Recent progress in the development of metal complexes as β-amyloid imaging probes in the brain.
TLDR
This review has discussed various radioactive complexes of 99mTc, 68Ga, 64Cu, 89Zr, and 111In, which were designed as Aβ imaging agents for PET and single photon emission computed tomography (SPECT) imaging, non-radioactive Re and Ru complexes as A β sensors using luminescence methods, and Gd3+ complexes as contrast agents for magnetic resonance imaging (MRI).
Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment
TLDR
Although the majority of radiotracers showed the ability to discriminate AD and MCI patients from healthy controls, they had various limitations that prevent the recommendation of a single technique or tracer as an optimal biomarker.
...
...

References

SHOWING 1-10 OF 93 REFERENCES
[18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer’s disease
TLDR
[18F]FMM PET imaging detects Aβ deposition in patients along the continuum from normal cognitive status to dementia of AD and discriminates AD patients from HC subjects, similar to [11C]PIB PET.
Flutemetamol (18F): a β-amyloid positron emission tomography tracer for Alzheimer's and dementia diagnosis.
TLDR
Flutemetamol (18F) (Vizamyl™) is a novel (18)F-labeled radiotracer for positron emission tomography (PET) that is rapidly taken up into the brain and binds to β-amyloid deposits and can be reliably quantified by the use of relative standard uptake value ratios.
Flutemetamol (18F): a β-amyloid positron emission tomography tracer for Alzheimer's and dementia diagnosis.
TLDR
Flutemetamol (18F) (Vizamyl) is a novel 18F-labeled radiotracer for positron emission tomography (PET) that is rapidly taken up into the brain and binds to beta-amyloid deposits, leading to the agent's approval to assist in the assessment of amyloid plaque pathology in AD patients.
In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [18F]flutemetamol
TLDR
The high specific activity of 18F-labelled amyloid imaging positron emission tomography (PET) agent [18F]flutemetamol did not provide a notable advantage in Tg2576 and APPswe-PS1dE9 mice compared to the previously evaluated structural analogue [11C].
Development of positron emission tomography β-amyloid plaque imaging agents.
TLDR
PiB is a PET radioligand that binds selectively and with high affinity to only fibrillar forms of Aβ that has demonstrated the usefulness of assessing the Aβ plaque status of subjects many years before the clinical diagnosis of probable AD.
Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography
TLDR
These data support the hypothesis that florbetapir-F18 provides comparable information with Pittsburgh Compound-B, and show highly significant group discrimination and correlation of regional uptake.
Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods
TLDR
PiB and florbetapir retention ratios were strongly associated in the same individuals, and this relationship was consistent across several data analysis methods, despite scan–rescan intervals of more than a year.
[18F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies
TLDR
Noninvasive in vivo PET imaging demonstrates strong concordance with histopathology for brain fibrillar amyloid β, supporting its promise as a tool to assist physicians with earlier detection of the disease process and making diagnostic decisions about concomitant AD and other diseases associated with brain amyloidsosis.
Pharmacokinetics of [18F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer’s disease
TLDR
Based on its pharmacokinetic profile, [18F]flutemetamol showed potential as a PET tracer for preclinical imaging and showed good brain uptake and was bound to Aβ deposits in the brain of Tg2576 mice, however, its high lipophilicity might complicate the analysis of PET data, particularly in small-animal imaging.
[18F]FLUTEMETAMOL AMYLOID PET IN SYMPTOMATIC ALZHEIMER'S DISEASE (AD) AND PATHOLOGICALLY PRECLINICAL AD (P-PREAD) IN COMPARISON TO NON-AD CONTROLS: IMPACT OF CEREBRAL AMYLOID ANGIOPATHY
...
...